BMY240705P40000
- 0.60
- +0.25+71.43%
Bristol-Myers Squibb Newsroom
Unusual Options Activity: AAL, RIVN and Others Attract Market Bets, AAL V/OI Ratio Reaches 170.7
EST Jul 3rd Afternoon Delivery - In the last two hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trends
Bristol-Myers Squibb To Go Ex-Dividend On July 5th, 2024 With 0.6 USD Dividend Per Share
July 2nd (Eastern Time) - $Bristol-Myers Squibb(BMY.US)$ is trading ex-dividend on July 5th, 2024.Shareholders of record on July 5th, 2024 will receive 0.6 USD dividend per share on August 1st, 2024.
Novo Nordisk, Eli Lilly Singled Out by Biden, Sanders Over Drug Prices
By Eleanor Laise Critique of obesity and diabetes drug prices avoids examining middlemen who influence cost and access Shares of Novo Nordisk and Eli Lilly & Co. dropped Tuesday after President Joe
Looking At Bristol-Myers Squibb's Recent Unusual Options Activity
Financial giants have made a conspicuous bearish move on Bristol-Myers Squibb. Our analysis of options history for Bristol-Myers Squibb (NYSE:BMY) revealed 8 unusual trades.Delving into the details, w
J&J Says Carvykti Beat Standard Drugs in Late-stage Blood Cancer Trial
Eisai Receives Rights to Antibody Drug Conjugate After Bristol Ends Collaboration
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities.
What the Options Market Tells Us About Bristol-Myers Squibb
Financial giants have made a conspicuous bearish move on Bristol-Myers Squibb.
Alnylam, Lilly, AstraZeneca Among Best Performing Pharmas, Biotechs in Q2
Rising Drug Costs Force a Third of Americans to Leave Prescriptions Unfilled: Report
Novo Nordisk Buys 2seventy's Hemophilia A Program, Divestiture Supports Exclusive Focus On Abecma
On Thursday, 2seventy Bio Inc. (NASDAQ:TSVT) completed the asset purchase agreement with Novo Nordisk A/S (NYSE:NVO).
Purple Biotech Says Interim Data From Pancreatic Cancer Drug Study Shows Promise
Purple Biotech (PPBT) said Thursday that additional interim data from a mid-stage study of its experimental drug CM24, combined with Bristol Myers Squibb's (BMY) nivolumab and chemotherapy for pancrea
Novo Nordisk Buys 2seventy Bio's Hemophilia A Program
2seventy Bio Sells Hemophilia A Candidate, Gene Editing Technology to Novo Nordisk; Shares Rise After Hours
2seventy bio (TSVT) said late Wednesday it has sold its Hemophilia A program and rights to its in-vivo gene-editing technology outside of oncology and gene-editing for autologous or allogeneic cell th
Merck Didn't Publicize the Results of a Key Cancer Trial -- Barrons.com
By Josh Nathan-Kazis Over the years, Merck has run dozens of clinical trials for Keytruda, its groundbreaking cancer immunotherapy. Those studies have earned the drug regulatory approval in 17 types
Top Midday Stories: Southwest Cuts Q2 Guidance; HHS to Lower Costs for Medicare Enrollees on 64 Drugs; Bosch Weighing Acquisition Offer for Whirlpool; Novo Nordisk to Record $816.2 Million Impairment
All three major US stock indexes were down in late morning trading as investors wait a fresh batch of inflation data on Friday with the release of the personal consumption expenditures price index for
Biden Administration to Lower Costs for 64 Prescription Drugs for Medicare Enrollees
10:34 AM EDT, 06/26/2024 (MT Newswires) -- Biden Administration to Lower Costs for 64 Prescription Drugs for Medicare Enrollees
Psoriasis Market to Register Incremental Growth by 2034, Predicts DelveInsight | Key Companies - AnaptysBio, Nimbus Lakshmi, Takeda, MoonLake Immunotherapeutics, Bristol-Myers Squibb, Amgen, Dermavant Sciences
DelveInsight's analysts estimate that the psoriasis market is poised to show significant growth, mainly attributed to increasing prevalence, recent drug approvals, and anticipated launch of novel the
FDA Approves Bristol Myers Squibb's Combination Therapy For Colorectal Cancer Patients With Certain Type Of Gene Mutation
Friday, the FDA granted accelerated approval to Bristol Myers Squibb & Co's (NYSE:BMY) Krazati (adagrasib) in combination with cetuximab as a targeted treatment option for adult patients with KRASG12C
Express News | Bristol-Myers Squibb's KRAS inhibitor receives FDA approval again.